Immuno-Oncology

The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1.

cancer vaccine | Image credit: IO Biotech
From “Super Skeptical” Beginnings, a New Immune-Modulatory Vaccine Awaits Phase 3 Results

May 3rd 2025

Round FDA approval stamp in blue ink | Image Credit: © Surendra - stock.adobe.com
FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

March 31st 2025

Travis Osterman, DO, MS, FAMIA, FASCO
Leveraging AI to Optimize Precision Immunotherapy at Vanderbilt

October 25th 2024

Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials
Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials

September 15th 2024

More News

VEGF Inhibition in NSCLC
July 18th 2018

VEGF Inhibition in NSCLC

The Phase 3 REVEL Trial in NSCLC
July 18th 2018

The Phase 3 REVEL Trial in NSCLC

Ramucirumab in Relapsed/Refractory NSCLC
July 18th 2018

Ramucirumab in Relapsed/Refractory NSCLC

Bevacizumab in NSCLC
July 18th 2018

Bevacizumab in NSCLC

Significance of KEYNOTE-189 in NSCLC
July 18th 2018

Significance of KEYNOTE-189 in NSCLC

Opdivo, Yervoy Combination Approved for Certain Colorectal Cancers
July 12th 2018

Opdivo, Yervoy Combination Approved for Certain Colorectal Cancers

Samantha DiGrande
Yesterday, drug manufacturer Bristol-Myers Squibb announced that the FDA has approved the combination nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) for the treatment of adult and pediatric patients aged 12 years and older with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following a fluoropyrimidine, oxaliplatin, or irinotecan-based chemotherapy treatment.
FDA Grants Keytruda Priority Review to Treat Most Common Form of Liver Cancer
July 11th 2018

FDA Grants Keytruda Priority Review to Treat Most Common Form of Liver Cancer

Samantha DiGrande
The FDA has granted priority review for Keytruda (pembrolizumab) as a treatment for previously treated patients with advanced hepatocellular carcinoma (HCC).
BrainChild-01 Will Evaluate CAR T Cells in Pediatric CNS Tumors
July 5th 2018

BrainChild-01 Will Evaluate CAR T Cells in Pediatric CNS Tumors

Surabhi Dangi-Garimella, PhD
The trial is designed to test chimeric antigen receptor (CAR) T-cell therapy in children and young adults with relapsed/refractory brain and central nervous system (CNS) tumors, wherein the modified CAR T cells will be directly injected at the site of tumor resection or into the ventricular system of the CNS.
First Immunotherapy Combination Demonstrates Improved PFS in Triple-Negative Breast Cancer
July 2nd 2018

First Immunotherapy Combination Demonstrates Improved PFS in Triple-Negative Breast Cancer

Jaime Rosenberg
Atezolizumab, in combination with chemotherapy, significantly reduced the risk of disease progression and mortality in patients with metastatic triple-negative breast cancer.
AbbVie and Calibr to Collaborate on CAR T-Cell Development
June 29th 2018

AbbVie and Calibr to Collaborate on CAR T-Cell Development

Samantha DiGrande
Drug manufacturer AbbVie, and a nonprofit drug discovery division of Scripps Research, Calibr, announced earlier this week that they are partnering to develop chimeric antigen receptor (CAR-T) cell therapies primarily aimed at treating cancer, particularly, solid tumors.
Tecentriq–Chemotherapy Combination Demonstrates Increased Survival in ES-SCLC
June 28th 2018

Tecentriq–Chemotherapy Combination Demonstrates Increased Survival in ES-SCLC

Samantha DiGrande
This week, drug maker Roche released positive data from its phase 3 IMpower133 study that investigated an immunotherapy-based combination of atezolizumab (Tecentriq) and chemotherapy in the treatment of extensive-stage small cell lung cancer (ES-SCLC).
Immunotherapy-Based Combination Improves Survival in SCLC for First Time in Phase 3 Study
June 25th 2018

Immunotherapy-Based Combination Improves Survival in SCLC for First Time in Phase 3 Study

Jaime Rosenberg
First-line treatment with atezolizumab plus chemotherapy helped patients with previously untreated extensive-stage small cell lung cancer (SCLC) live significantly longer than those treated with chemotherapy alone.
FDA Warns Efficacy Concerns in Some Patients Taking Keytruda, Tecentriq
June 21st 2018

FDA Warns Efficacy Concerns in Some Patients Taking Keytruda, Tecentriq

Samantha DiGrande
In a statement released yesterday, the FDA has announced that it is restricting the use of pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy.
Nivolumab Gains First Indication in China for NSCLC
June 20th 2018

Nivolumab Gains First Indication in China for NSCLC

Samantha DiGrande
Last week, Bristol-Myers Squibb announced that the China National Drug Administration approved the country’s first immuno-oncology and first PD-1 therapy, nivolumab (Opdivo), for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).
RA Drug May Reduce Toxicity Caused By CAR T Treatment
June 15th 2018

RA Drug May Reduce Toxicity Caused By CAR T Treatment

Samantha DiGrande
Last year, the FDA expanded the indications of rheumatoid arthritis (RA) drug tocilizumab (Actemra) to include the treatment of cytokine release syndrome (CRS) caused by CAR T-cell therapy. Recently, 2 studies have identified another rheumatoid arthritis drug that could be more effective in the treatment of CRS.
Pembrolizumab Indications Expand to Include Cervical Cancer
June 13th 2018

Pembrolizumab Indications Expand to Include Cervical Cancer

Samantha DiGrande
Yesterday, the FDA announced that it has expanded the indications of pembrolizumab (Keytruda) to include recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1.
Genetic Analysis of Thyroid Cancer Suggests Personalized Treatment Possible
June 9th 2018

Genetic Analysis of Thyroid Cancer Suggests Personalized Treatment Possible

Samantha DiGrande
In April, researchers from the University of Colorado Cancer Center completed the largest study of thyroid cancer genetics to date, the results of which were published in Clinical Cancer Research.
Gene Editing Could Limit Toxicity of CAR T Treatment in AML
June 6th 2018

Gene Editing Could Limit Toxicity of CAR T Treatment in AML

Samantha DiGrande
A study recently published in Cell investigated the deletion of the CD33 protein to enable CAR T-cells to more accurately target and attack cancerous cells in patients with n acute myeloid leukemia (AML).
This Week in Managed Care: June 1, 2018
June 1st 2018

This Week in Managed Care: June 1, 2018

This week, the top managed care stories include Senator Bill Cassidy's new plan to lower healthcare costs; policy recommendations from the American Diabetes Association on how to lower insulin prices; and coverage from the American Society of Clinical Oncology annual meeting.
New Immunotherapy Increases Survival Time for Patients With Brain Cancer
June 1st 2018

New Immunotherapy Increases Survival Time for Patients With Brain Cancer

Samantha DiGrande
A new immunotherapy referred to as the "Toca regimen" is being investigated in a phase 2/3 randomized, multicenter, open-label trial.
Pembrolizumab Improved OS, PFS as First-Line Treatment in NSCLC
May 30th 2018

Pembrolizumab Improved OS, PFS as First-Line Treatment in NSCLC

Jaime Rosenberg
Pembrolizumab significantly improved overall survival (OS) and progression-free survival (PFS) as first-line treatment for squamous non–small cell lung cancer (NSCLC) in the pivotal phase 3 KEYNOTE-407 trial.
Immune Checkpoint Inhibitors Demonstrate Better Response in Men Than Women
May 17th 2018

Immune Checkpoint Inhibitors Demonstrate Better Response in Men Than Women

Jaime Rosenberg
While immune checkpoint inhibitors significantly improve overall survival in both sexes, the magnitude of benefit is dependent on sex, according to new study findings.
Study Finds Rapid Uptake of Anti–PD-1 Agents Following FDA Approval
May 14th 2018

Study Finds Rapid Uptake of Anti–PD-1 Agents Following FDA Approval

Jaime Rosenberg
In the 4 months following their approvals, pembrolizumab and nivolumab reached more than 60% of eligible patients with melanoma, non-small cell lung cancer, and renal cell carcinoma.
CAR T Therapy Case Study Shows Early Success in Treatment of Acute Myeloid Leukemia
May 9th 2018

CAR T Therapy Case Study Shows Early Success in Treatment of Acute Myeloid Leukemia

Samantha DiGrande
A new case study found that an acute myeloid leukemia patient has remained cancer free for 9 months following treatment with the chimeric antigen receptor (CAR) T-cell treatment, CYAD-01, and a bone marrow transplant.
FDA Approves CAR T-Cell Treatment Kymriah for Adult B-Cell Lymphoma
May 2nd 2018

FDA Approves CAR T-Cell Treatment Kymriah for Adult B-Cell Lymphoma

Jaime Rosenberg
Tisagenlecleucel, sold as Kymriah, has gained its second indication following the FDA's approval of the chimeric antigen receptor T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, the most common form of non-Hodgkin lymphoma.
FDA Grants Priority Review for Pembrolizumab, Chemotherapy Combination in NSCLC
April 30th 2018

FDA Grants Priority Review for Pembrolizumab, Chemotherapy Combination in NSCLC

Jaime Rosenberg
The FDA has granted priority review to Merck’s supplemental Biologics License Application for pembrolizumab (Keytruda) in combination with pemetrexed (Alimta) and platinum chemotherapy as first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC). The FDA is set to make a decision by September 23.
Site Logo
April 21st 2018

Dr Houston Holmes Discusses CAR T Therapy Adoption and Education

Laura Joszt, MA
With chimeric antigen receptor (CAR) T-cell therapy being so new, there is going to be a learning curve as providers become more educated about the treatments, the manufacturing process, and the toxicities, Houston Holmes, MD, MBA, FACP, a medical oncologist with Texas Oncology, explained at the Community Oncology Alliance’s (COA) 2018 Community Oncology Conference.
Site Logo
February 25th 2018

Future Shock: Embracing Disruption in the Immunotherapy Revolution

Joseph Alvarnas, MD
Dr Alvarnas is editor in chief and director of Value-Based Analytics at City of Hope, Duarte, California.
Site Logo
February 21st 2018

Current Landscape of Immuno-Oncology in Advanced Melanoma

Site Logo
February 21st 2018

Contemporary Diagnosis and Management of Advanced Melanoma

<1
...
89101112131415>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo